BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)

Clinical trials for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) explained in plain language.

Never miss a new study

Get alerted when new BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) trials appear

Sign up with your email to follow new studies for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet recruiting 1

New drug duo tested in fight against rare, aggressive blood cancer

Disease control Not yet recruiting

This study is testing whether combining two drugs, tagraxofusp and venetoclax, is safe and effective for adults newly diagnosed with a rare and aggressive blood cancer called BPDCN. The main goal is to see if this combination leads to a complete remission after three months of tr…

Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)

Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)

Get alerted when new BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) trials appear

New drug duo tested in fight against rare, aggressive blood cancer